GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 35,506 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 35,506 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92. Following the transaction, the chief financial officer now owns 2,472 shares in the company, valued at $231,923.04. The trade was a 93.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Trading Down 7.4 %

NASDAQ WGS traded down $7.19 during trading hours on Friday, reaching $89.38. The company’s stock had a trading volume of 725,309 shares, compared to its average volume of 909,701. The stock has a market cap of $2.46 billion, a P/E ratio of -28.74 and a beta of 2.02. The firm has a fifty day simple moving average of $78.01 and a 200-day simple moving average of $53.19. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 52 week low of $2.85 and a 52 week high of $98.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.82) EPS. Equities analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of WGS. Acadian Asset Management LLC bought a new position in shares of GeneDx during the 2nd quarter worth approximately $34,000. CWM LLC bought a new position in GeneDx during the third quarter worth $89,000. SG Americas Securities LLC acquired a new stake in GeneDx in the third quarter worth $198,000. Point72 DIFC Ltd acquired a new position in shares of GeneDx during the third quarter valued at about $220,000. Finally, Palumbo Wealth Management LLC bought a new position in shares of GeneDx during the 3rd quarter worth about $287,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group raised their target price on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company boosted their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Finally, Craig Hallum lifted their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and an average price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.